The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress

被引:75
作者
Scribner, AW
Loscalzo, J [1 ]
Napoli, C
机构
[1] Boston Univ, Sch Med, Evans Dept Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA
[2] Univ Naples, Dept Med, I-80131 Naples, Italy
关键词
angiotensin-converting enzyme; endothelium; nitric oxide (NO); oxidative stress;
D O I
10.1016/j.ejphar.2003.10.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiotensin-converting enzyme (ACE) inhibitors effectively interfere with the renin-angiotensin system and exert various beneficial actions on vascular structure and function beyond their blood pressure-lowering effects. Data from experimental studies showed that angiotensin-converting enzyme inhibitors can attenuate the development of atherosclerosis in a wide range of species. The postulated mechanisms of this atheroprotective effect are the antioxidant actions of angiotensin-converting enzyme inhibitors and their enhancement of the endothelial elaboration of bioactive nitric oxide. The aim of this study was to assess the comparative effects of three angiotensin-converting enzyme inhibitors on endothelial nitric oxide production and action, and on endothelial oxidative stress. Using bovine aortic endothelial cells in culture grown to confluence, we examined the effects of 1, 10, 30 and 60 muM of each of captopril, zofenopril and enalapril on nitrite/nitrate accumulation in the media, cyclic GMP accumulation in the cell lysate, and F-2-isoprostanes in lipid extracts from the cells. Results showed that the sulfhydryl angiotensin-converting enzyme inhibitor zofenopril has unique properties compared with captopril and enalapril. This compound improves nitric oxide production and bioactivity, and does so in conjunction with decreased endothelial cell oxidant stress. The biochemical basis for this protective mechanism is not entirely clear; however, these actions suggest that zofenopril may reduce endothelial effects of risk factors for atherothrombotic disease. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:95 / 99
页数:5
相关论文
共 33 条
[1]   EFFECTS OF CAPTOPRIL ON ATHEROSCLEROSIS IN CYNOMOLGUS MONKEYS [J].
ABERG, G ;
FERRER, P .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 :S65-S72
[2]   THE EFFECT OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ZOFENOPRIL ON MORTALITY AND MORBIDITY AFTER ANTERIOR MYOCARDIAL-INFARCTION [J].
AMBROSIONI, E ;
BORGHI, C ;
MAGNANI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (02) :80-85
[3]   Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension [J].
Borghi, C ;
Bacchelli, S ;
Esposti, DD ;
Bignamini, A ;
Magnani, B ;
Ambrosioni, E .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (07) :665-672
[4]   Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure [J].
Buikema, H ;
Monnink, SHJ ;
Tio, RA ;
Crijns, HJGM ;
de Zeeuw, D ;
van Gilst, WH .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (08) :1999-2007
[5]   ACE-INHIBITION WITH PERINDOPRIL AND ATHEROGENESIS-INDUCED STRUCTURAL AND FUNCTIONAL-CHANGES IN MINIPIG ARTERIES [J].
CHARPIOT, P ;
ROLLAND, PH ;
FRIGGI, A ;
PIQUET, P ;
SCALBERT, E ;
BODARD, H ;
BARLATIER, A ;
LATRILLE, V ;
TRANIER, P ;
MERCIER, C ;
LUCCIONI, R ;
CALAF, R ;
GARCON, D .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (08) :1125-1138
[6]   ANTIATHEROGENIC EFFECT OF CAPTOPRIL IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT [J].
CHOBANIAN, AV ;
HAUDENSCHILD, CC ;
NICKERSON, C ;
DRAGO, R .
HYPERTENSION, 1990, 15 (03) :327-331
[7]   ANTIOXIDANT EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS - FREE-RADICAL AND OXIDANT SCAVENGING ARE SULFHYDRYL DEPENDENT, BUT LIPID-PEROXIDATION IS INHIBITED BY BOTH SULFHYDRYL-CONTAINING AND NONSULFHYDRYL-CONTAINING ACE INHIBITORS [J].
CHOPRA, M ;
BESWICK, H ;
CLAPPERTON, M ;
DARGIE, HJ ;
SMITH, WE ;
MCMURRAY, J .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 19 (03) :330-340
[8]   Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications [J].
Cracowski, JL ;
Durand, T ;
Bessard, G .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (08) :360-366
[9]  
CUSHMAN DW, 1989, BR J CLIN PHARM, V28, P115
[10]   ANGIOTENSIN-II INDUCES SMOOTH-MUSCLE CELL-PROLIFERATION IN THE NORMAL AND INJURED RAT ARTERIAL-WALL [J].
DAEMEN, MJAP ;
LOMBARDI, DM ;
BOSMAN, FT ;
SCHWARTZ, SM .
CIRCULATION RESEARCH, 1991, 68 (02) :450-456